These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

826 related items for PubMed ID: 22860764

  • 1. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P, van Zanten SV, Mattsson H, Wernersson B.
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [Abstract] [Full Text] [Related]

  • 2. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
    Sharma P, Johnson DA, Monyak JT, Illueca M.
    Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
    [Abstract] [Full Text] [Related]

  • 3. Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis--results from the maintenance phase of the EXPO study.
    Labenz J, Armstrong D, Zetterstrand S, Eklund S, Leodolter A.
    Aliment Pharmacol Ther; 2009 Jun 01; 29(11):1165-71. PubMed ID: 19298581
    [Abstract] [Full Text] [Related]

  • 4. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
    Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, Rossiter G, Lu Y.
    Aliment Pharmacol Ther; 2011 Jan 01; 33(2):203-12. PubMed ID: 21114792
    [Abstract] [Full Text] [Related]

  • 5. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, Bianchi Porro G, Italian Rabeprazole Study Group.
    Dig Liver Dis; 2005 Oct 01; 37(10):741-50. PubMed ID: 16024305
    [Abstract] [Full Text] [Related]

  • 6. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
    Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, Nauclér E, Adler J, Eklund S.
    Aliment Pharmacol Ther; 2005 Nov 01; 22(9):803-11. PubMed ID: 16225489
    [Abstract] [Full Text] [Related]

  • 7. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D, Paré P, Pericak D, Pyzyk M, Canadian Pantoprazole GERD Study Group.
    Am J Gastroenterol; 2001 Oct 01; 96(10):2849-57. PubMed ID: 11695354
    [Abstract] [Full Text] [Related]

  • 8. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
    Fass R, Chey WD, Zakko SF, Andhivarothai N, Palmer RN, Perez MC, Atkinson SN.
    Aliment Pharmacol Ther; 2009 Jun 15; 29(12):1261-72. PubMed ID: 19392864
    [Abstract] [Full Text] [Related]

  • 9. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
    Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L, FAST Trial Investigators.
    Aliment Pharmacol Ther; 2002 Mar 15; 16(3):445-54. PubMed ID: 11876697
    [Abstract] [Full Text] [Related]

  • 10. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study.
    Labenz J, Armstrong D, Zetterstrand S, Eklund S, Leodolter A.
    Aliment Pharmacol Ther; 2009 May 01; 29(9):959-66. PubMed ID: 19222417
    [Abstract] [Full Text] [Related]

  • 11. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
    DeVault KR.
    Aliment Pharmacol Ther; 2006 Mar 01; 23 Suppl 1():33-9. PubMed ID: 16483268
    [Abstract] [Full Text] [Related]

  • 12. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease.
    Pace F, Negrini C, Wiklund I, Rossi C, Savarino V, ITALIAN ONE INVESTIGATORS STUDY GROUP.
    Aliment Pharmacol Ther; 2005 Aug 15; 22(4):349-56. PubMed ID: 16098002
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
    Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, Ito M, Fujiwara Y, Wada T, Nagahara A, Hongo M, Chiba T, Kinoshita Y, ACID-RELATED SYMPTOM (ARS) RESEARCH GROUP.
    Aliment Pharmacol Ther; 2007 Jul 01; 26(1):69-77. PubMed ID: 17555423
    [Abstract] [Full Text] [Related]

  • 14. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
    Hongo M, Miwa H, Kusano M, J-FAST group.
    J Gastroenterol Hepatol; 2012 May 01; 27(5):913-8. PubMed ID: 22142515
    [Abstract] [Full Text] [Related]

  • 15. Obesity does not affect treatment outcomes with proton pump inhibitors.
    Sharma P, Vakil N, Monyak JT, Silberg DG.
    J Clin Gastroenterol; 2013 Sep 01; 47(8):672-7. PubMed ID: 23442835
    [Abstract] [Full Text] [Related]

  • 16. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.
    Eggleston A, Katelaris PH, Nandurkar S, Thorpe P, Holtmann G, Treat Study Group.
    Aliment Pharmacol Ther; 2009 May 01; 29(9):967-78. PubMed ID: 19210493
    [Abstract] [Full Text] [Related]

  • 17. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.
    Aanen MC, Weusten BL, Numans ME, de Wit NJ, Samsom M, Smout AJ.
    J Clin Gastroenterol; 2008 May 01; 42(5):441-7. PubMed ID: 18344896
    [Abstract] [Full Text] [Related]

  • 18. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis.
    Gardner JD, Gallo-Torres H, Sloan S, Robinson M, Miner PB.
    Aliment Pharmacol Ther; 2003 Nov 01; 18(9):891-905. PubMed ID: 14616153
    [Abstract] [Full Text] [Related]

  • 19. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
    Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG.
    Am J Gastroenterol; 2002 Mar 01; 97(3):575-83. PubMed ID: 11922549
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
    Wada T, Sasaki M, Kataoka H, Tanida S, Itoh K, Ogasawara N, Oshima T, Togawa S, Kubota E, Yamada T, Mori Y, Fujita F, Ohara H, Nakao H, Sobue S, Joh T, Itoh M.
    Aliment Pharmacol Ther; 2005 Jun 01; 21 Suppl 2():2-9. PubMed ID: 15943840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.